Biologics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biologics

EMA Works to Speed Up Ebola Treatment

October 20, 2014

The agency recommends that companies developing drugs to treat Ebola apply for orphan drug designation.

Biopharma Manufacturers Respond to Ebola Crisis

October 2, 2014

Pharmaceutical Technology

Demand for new therapies and vaccines spotlights production challenges.

FDA and NIH Win Award for IP Licensing of Meningitis Vaccine

September 26, 2014

Partnership is awarded for licensing of low-cost vaccine for the treatment of bacterial meningitis.

USP Supports WHO Biologics Naming Proposal

September 25, 2014

USP expresses its support for a consensus-based global approach to the naming of biologics.

Risk Reduction Top Driver for Biopharmaceutical Raw Material Development

August 2, 2014

Pharmaceutical Technology

Customers are looking to reduce risk, increase performance, and optimize productivity.

Technologies Key for Biologics to Meet Expectations

August 1, 2014
Pharmaceutical Technology

Representatives of contract service organizations that develop biologic-based drugs discussed technology trends such as high-throughput screening and single-use systems.

Biosimilar Development: 10 Years On

August 1, 2014

Pharmaceutical Technology Europe

With a number of branded biologics hanging at the patent cliff, the future looks promising for biosimilars.

Emerging Opportunities with Biosimilars

August 1, 2014

Pharmaceutical Technology Europe

To realise the full potential for biosimilars, stakeholders must build a better understanding of biosimilars and to take a comprehensive view of how these important medicines can fit into treatment pathways.

Biotech Industry Forms International Council

July 10, 2014

New International Council on Biotechnology Associations advocates biotechnology growth.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here